AR067613A1 - Inhibidores de adn-pk, uso y sintesis de los mismos - Google Patents
Inhibidores de adn-pk, uso y sintesis de los mismosInfo
- Publication number
- AR067613A1 AR067613A1 ARP080103124A ARP080103124A AR067613A1 AR 067613 A1 AR067613 A1 AR 067613A1 AR P080103124 A ARP080103124 A AR P080103124A AR P080103124 A ARP080103124 A AR P080103124A AR 067613 A1 AR067613 A1 AR 067613A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- synthesis
- same
- heterocyclyl
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de formula (1) en donde: R1 y R2 se seleccionan de manera independiente entre hidrogeno, un grupo alquilo C1-7, heterociclilo C3-20 o arilo C5-20 opcionalmente sustituido, o juntos pueden formar, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalmente sustituido que tiene entre 4 y 8 átomos de anillo; X es CH o N; n es 1 o 2; RC1 y RC2 se seleccionan de manera independiente entre H y metilo; cuando X es N, RX se selecciona del grupo que consiste de H, y un grupo opcionalmente sustituido de alquilo C1-7, heterociclilo C3-20, arilo C5-20, acilo, éster, amido y sulfonilo; y cuando X es CH, RX se selecciona del grupo que consiste de H, y un grupo opcionalmente sustituido de alquilo C1-7, heterociclilo C3-20, arilo C5-20, acilo, éster, amido, sulfonilo, amino y éter.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95063107P | 2007-07-19 | 2007-07-19 | |
| US3656008P | 2008-03-14 | 2008-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067613A1 true AR067613A1 (es) | 2009-10-14 |
Family
ID=39791057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103124A AR067613A1 (es) | 2007-07-19 | 2008-07-18 | Inhibidores de adn-pk, uso y sintesis de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090042865A1 (es) |
| EP (1) | EP2176254A1 (es) |
| JP (1) | JP2010533694A (es) |
| KR (1) | KR20100063701A (es) |
| CN (1) | CN101754964A (es) |
| AR (1) | AR067613A1 (es) |
| AU (1) | AU2008277418A1 (es) |
| BR (1) | BRPI0814797A2 (es) |
| CA (1) | CA2693926A1 (es) |
| CL (1) | CL2008002130A1 (es) |
| RU (1) | RU2009149210A (es) |
| TW (1) | TW200918528A (es) |
| UY (1) | UY31232A1 (es) |
| WO (1) | WO2009010761A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| ATE461193T1 (de) * | 2003-08-13 | 2010-04-15 | Kudos Pharm Ltd | Aminopyrone und ihre verwendung als atm inhibitoren |
| TW200616986A (en) * | 2004-09-20 | 2006-06-01 | Kudos Pharm Ltd | DNA-pk inhibitors |
| JP2008529995A (ja) * | 2005-02-09 | 2008-08-07 | クドス ファーマシューティカルズ リミテッド | Ａｔｍ阻害剤 |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| KR20100033419A (ko) | 2007-07-19 | 2010-03-29 | 메타볼렉스, 인코포레이티드 | 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체 |
| US8410127B2 (en) | 2009-10-01 | 2013-04-02 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| WO2011137428A1 (en) * | 2010-04-30 | 2011-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating hiv infection: inhibition of dna dependent protein kinase |
| ES2676209T3 (es) | 2010-06-23 | 2018-07-17 | Metabolex Inc. | Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| MX371331B (es) | 2012-04-24 | 2020-01-27 | Vertex Pharma | Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk). |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| CN104892589A (zh) * | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | 一类杂环化合物、其制备方法和用途 |
| US10292983B2 (en) | 2016-08-03 | 2019-05-21 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| JP2019529475A (ja) | 2016-09-27 | 2019-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法 |
| CN111053903A (zh) * | 2019-12-26 | 2020-04-24 | 深圳市纳诺艾医疗科技有限公司 | 一种携带共振原子的核酸类似物的化合物的应用 |
| TW202235074A (zh) * | 2021-01-05 | 2022-09-16 | 大陸商山東軒竹醫藥科技有限公司 | 多環類激酶抑制劑 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0753725B2 (ja) * | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
| US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| US5703075A (en) * | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| US5302613A (en) * | 1990-06-29 | 1994-04-12 | The Upjohn Company | Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones |
| US5252735A (en) * | 1990-06-29 | 1993-10-12 | The Upjohn Company | Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones |
| ATE203904T1 (de) * | 1993-04-09 | 2001-08-15 | Toyama Chemical Co Ltd | Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen |
| US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| JP4103968B2 (ja) * | 1996-09-18 | 2008-06-18 | 株式会社半導体エネルギー研究所 | 絶縁ゲイト型半導体装置 |
| US6348311B1 (en) * | 1999-02-10 | 2002-02-19 | St. Jude Childre's Research Hospital | ATM kinase modulation for screening and therapies |
| US6387640B1 (en) * | 1999-02-10 | 2002-05-14 | St. Jude Children's Research Hospital | ATM kinase modulation for screening and therapies |
| US6333180B1 (en) * | 1999-12-21 | 2001-12-25 | International Flavors & Fragrances Inc. | Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate |
| KR20030017569A (ko) * | 2000-06-28 | 2003-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 카르베딜올 |
| GB0119863D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| US7049313B2 (en) * | 2002-02-25 | 2006-05-23 | Kudos Pharmaceuticals Ltd. | ATM inhibitors |
| ES2357057T3 (es) * | 2002-04-30 | 2011-04-15 | Kudos Pharmaceuticals Limited | Derivados de ftalazinona. |
| ATE461193T1 (de) * | 2003-08-13 | 2010-04-15 | Kudos Pharm Ltd | Aminopyrone und ihre verwendung als atm inhibitoren |
| TW200616986A (en) * | 2004-09-20 | 2006-06-01 | Kudos Pharm Ltd | DNA-pk inhibitors |
| JP2008529995A (ja) * | 2005-02-09 | 2008-08-07 | クドス ファーマシューティカルズ リミテッド | Ａｔｍ阻害剤 |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| JP5781720B2 (ja) * | 2008-12-15 | 2015-09-24 | ルネサスエレクトロニクス株式会社 | 半導体装置及び半導体装置の製造方法 |
-
2008
- 2008-07-17 UY UY31232A patent/UY31232A1/es not_active Application Discontinuation
- 2008-07-18 KR KR1020107003763A patent/KR20100063701A/ko not_active Withdrawn
- 2008-07-18 BR BRPI0814797-3A2A patent/BRPI0814797A2/pt not_active Application Discontinuation
- 2008-07-18 RU RU2009149210/04A patent/RU2009149210A/ru not_active Application Discontinuation
- 2008-07-18 JP JP2010516580A patent/JP2010533694A/ja not_active Withdrawn
- 2008-07-18 CN CN200880024849A patent/CN101754964A/zh active Pending
- 2008-07-18 EP EP08775986A patent/EP2176254A1/en not_active Withdrawn
- 2008-07-18 US US12/175,542 patent/US20090042865A1/en not_active Abandoned
- 2008-07-18 TW TW097127524A patent/TW200918528A/zh unknown
- 2008-07-18 CL CL2008002130A patent/CL2008002130A1/es unknown
- 2008-07-18 AU AU2008277418A patent/AU2008277418A1/en not_active Abandoned
- 2008-07-18 AR ARP080103124A patent/AR067613A1/es unknown
- 2008-07-18 CA CA2693926A patent/CA2693926A1/en not_active Abandoned
- 2008-07-18 WO PCT/GB2008/002459 patent/WO2009010761A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20090042865A1 (en) | 2009-02-12 |
| AU2008277418A1 (en) | 2009-01-22 |
| UY31232A1 (es) | 2009-03-02 |
| JP2010533694A (ja) | 2010-10-28 |
| CA2693926A1 (en) | 2009-01-22 |
| WO2009010761A1 (en) | 2009-01-22 |
| RU2009149210A (ru) | 2011-08-27 |
| CL2008002130A1 (es) | 2009-01-02 |
| TW200918528A (en) | 2009-05-01 |
| KR20100063701A (ko) | 2010-06-11 |
| EP2176254A1 (en) | 2010-04-21 |
| BRPI0814797A2 (pt) | 2015-02-03 |
| CN101754964A (zh) | 2010-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067613A1 (es) | Inhibidores de adn-pk, uso y sintesis de los mismos | |
| ES2618630T3 (es) | Composiciones terapéuticas y métodos de uso relacionados | |
| EA200971100A1 (ru) | Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1) | |
| JO2947B1 (en) | Compounds corresponding to cyclopamine | |
| UY31603A1 (es) | Derivados de ftalazinona | |
| NO20071873L (no) | DNA-PK inhibotorer. | |
| AR106942A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
| DE602004026071D1 (de) | Aminopyrone und ihre verwendung als atm inhibitoren | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| UY31014A1 (es) | Derivados de ftalazinona | |
| EA201070839A1 (ru) | Новые производные ацилцианопирролидинов | |
| CY1117157T1 (el) | Υποκατεστημενο παραγωγο ισοκινολινης | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| AR083760A1 (es) | Agentes antibacterianos y composiciones farmaceuticas | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| ES2530398T3 (es) | Pirrolidin-2-onas 4-sustituidas y su uso | |
| UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| SV2010003459A (es) | Derivados de pirimidina 934 | |
| AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
| TW200638938A (en) | ATM inhibitors | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| CO6331307A2 (es) | Derivados de imidazo[1,2alfa]piridin-2-carboxamidas su preparacion y su aplicacion en terapeutica | |
| MX2013007296A (es) | Derivado novedoso de isoquinolina sustituido. | |
| AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos | |
| CL2004000160A1 (es) | Derivados de avermectina sustituidos en posicion 4' y 4'', composicion que los contiene, utiles como plaguicidas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |